Results 111 to 120 of about 26,268,555 (308)

Corrigendum: Racial and Sex Differences in the Response to First-Line Antihypertensive Therapy

Frontiers in Cardiovascular Medicine, 2021
John S. Clemmer, W. Andrew Pruett, Seth T. Lirette   +2 more
doaj   +1 more source

Catheter ablation of common atrioventricular nodal reentry tachycardia using the conventional method

Zanco Journal of Medical Sciences, 2019
Background and objective: Atrioventricular nodal reentry tachycardia is the commonest type of supraventricular tachycardia referred to the electrophysiology laboratory.
Amar Alhamdi
doaj  

Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

BMC Medicine, 2018
Background For patients starting treatment for depression, current guidelines recommend titrating the antidepressant dosage to the maximum of the licenced range if tolerated.
Tadashi Kato, Toshi A. Furukawa, Akio Mantani, Ken’ichi Kurata, Hajime Kubouchi, Susumu Hirota, Hirotoshi Sato, Kazuyuki Sugishita, Bun Chino, Kahori Itoh, Yoshio Ikeda, Yoshihiro Shinagawa, Masaki Kondo, Yasumasa Okamoto, Hirokazu Fujita, Motomu Suga, Shingo Yasumoto, Naohisa Tsujino, Takeshi Inoue, Noboru Fujise, Tatsuo Akechi, Mitsuhiko Yamada, Shinji Shimodera, Norio Watanabe, Masatoshi Inagaki, Kazuhira Miki, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Aran Tajika, Kiyomi Shinohara, Naohiro Yonemoto, Shiro Tanaka, Qi Zhou, Gordon H. Guyatt, for the SUN☺D Investigators   +35 more
doaj   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer

BMC Cancer
Background The 5-fuorouracil, oxaliplatin and irinotecan (FOLFOXIRI) regimen is the standard first-line treatment for advanced pancreatic cancer (APC).
Bi-Yang Cao, Qi Cao, Xiao-Ting Ma, Kai Ou, Wen-Wei Yang, Le-Tian Zhang, Jing-Yu Lu, Zhi-Chao Jiang, Wen Zhang, Jie Zhang, Qi Wang, Li-Zhen Gao, Lin Yang   +12 more
doaj   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P., Munderi, P., Pillay, D., Ndembi, N., Nkurunziza, P., Ndembi, N, Pattery, T, Dunn, DT, van Cauwenberge, A, Gilks, C. F., Gilks, CF, Awio, P, Munderi, P, Nkurunziza, P, Kaleebu, P., Pillay, D, Goodall, RL, DART Virology Group and Trial Teams, Kaleebu, P, Goodall, R. L., Kityo, C., Dunn, D. T., Kityo, C, Pattery, T., van Cauwenberge, A., K. Mataruka, B. Kikaire, M. Nabankkema, H. Grosskurth, P. Khauka, M. Namyalo, C. Kityo, C. Parry, C. F. Gilks, M. Spyer, R. Magala, P. Kaleebu, R. L. Goodall, P. Nkurunziza, N. Ndembi, R. Goodall, A. Zalwango, T. Pattery, L. Generous, P. Awio, D. Dunn, D. Pillay, K. Fadhiru, G. Kabuye, L. Mugarura, G. Nassuna, M. Chirara, M. Katuramur, B. Magambo, J. Nkalubo, R. Massa, A. van Cauwenberge, E. Zalwango, V. Robertson, P. Munderi, D. Yirrell, R. Kasirye, D. M. Gibb, A. Kapaata, D. T. Dunn, D. Nsibambi, F. Lyagoba, T. Musunga, A.L. McCormick, M. Nakazibwe, C. Gilks   +70 more
core   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease

International Journal of COPD, 2020
Koichiro Takahashi,1 Masaru Uchida,2 Go Kato,3 Ayako Takamori,4 Takashi Kinoshita,5 Makoto Yoshida,6 Ryo Tajiri,4 Keisuke Kojima,7 Hiroshi Inoue,8 Hiromi Kobayashi,9 Hironori Sadamatsu,1 Hiroki Tashiro,1 Masahide Tanaka,1 Shinichiro Hayashi,10 Atsushi ...
Takahashi K, Uchida M, Kato G, Takamori A, Kinoshita T, Yoshida M, Tajiri R, Kojima K, Inoue H, Kobayashi H, Sadamatsu H, Tashiro H, Tanaka M, Hayashi S, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T   +17 more
doaj  

Translophagy—A potential link between autophagy impairment and translational errors

FEBS Letters, EarlyView.
Neurodegenerative diseases are characterised by the accumulation of abnormal proteins and protein aggregates, but their origin often remains unknown. We propose that selective autophagy removes damaged protein‐making machinery, preventing errors during protein synthesis.
Mykola V. Korolchuk, Gailing Ma, Robin Antrobus, Diego Manni, Marco Trevisan‐Herraz, Mustafa Khwaja, Max Brown, Gavin D. Richardson, Masaaki Komatsu, Daniel Erskine, Viktor I. Korolchuk, Tetsushi Kataura   +11 more
wiley   +1 more source

Osimertinib in first-line treatment—is a comparison not proof? [PDF]

Annals of Translational Medicine, 2018
Considerable progress has been made in the treatment of advanced non-small-cell lung carcinoma (NSCLC) harboring an epidermal growth factor receptor (EGFR) gene mutation (EGFR-NSCLC) since the publication of the BR21 trial (1). That trial showed erlotinib to have a modest effect compared with placebo in the second and subsequent lines of treatment in ...
openaire   +2 more sources